JinFang Pharmaceuticals-B(02595) Included in the Hong Kong Stock Connect Securities List

robot
Abstract generation in progress

Zhitong Finance APP News, Jingfang Medicine-B (02595) announced that, according to notices from the Shanghai Stock Exchange and the Shenzhen Stock Exchange, the company will be included in the list of eligible securities for the Stock Connect (Shanghai-Hong Kong and Shenzhen-Hong Kong) starting March 9, 2026. After being included in the Stock Connect, qualified investors from mainland China will be able to directly invest in the company’s shares through the Shanghai and Shenzhen Stock Exchanges.

Starting March 9, 2026, the company will also be included in multiple Hang Seng Index series components, such as the Hang Seng Composite Index, Hang Seng H-Share Index, and Hang Seng Innovation Pharmaceutical Index, as part of the Hang Seng Index Series.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin